摘要
我国从2009年开始实行基本药物制度,有利于解决用药贵、用药难等现实问题。但是基本药物普及性的提高更加突出了药物不良反应(ADR)监测的重要性,为保障用药安全,药品上市后的安全性再评价十分重要。为了加强国家基本药物ADR的监测工作,阐述我国基本药物ADR监测的现状及存在问题,并提出完善法律体系、明晰基本药物的遴选标准、提高各主体ADR认识的实施建议,为合理用药、保障公众健康提供指导。
In order to obtain drugs conveniently and cheaply,the national essential drug policy has been implemented formed in China since 2009.However,due to the improvement of national essential drug popularity,the adverse drug reaction（ADR） monitoring became more important,and the post-marketing safety re-evaluation is very important for protecting the health of patients.The aim of this article is to guide the rational use of drugs and protect human health,and the current status of ADR monitoring of national essential drugs is discussed.Some advices were provided to enhance the ADR monitoring of national essential drugs,including constituting policy system,detailing the national essential drug criteria,and encouraging the spontaneous reporting of ADRs.
出处
《药物评价研究》
CAS
2013年第5期386-388,共3页
Drug Evaluation Research
关键词
国家基本药物
不良反应
药物评价
药品监测
national essential drugs
adverse drug reaction
drug evaluation
drug monitoring
